WeVote
Log In

Bill

Bill

SF 56

A bill for an act relating to the right to try Act.

2025-2026 Regular Session Introduced by Jeff Taylor

SF 56 empowers terminally ill patients to access investigational drugs and treatments, enhancing their rights and improving collaboration with manufacturers and facilities.

Committee report approving bill, renumbered as SF 233.
#biologicalproducts #diseases #drugs #healthinsurance #informedconsent #medicalcare #rights #terminalillnesses #third-partyadministrators
0
WeVote Research Nonpartisan
Bill Summary · SF 56

Summary of SF 56 - Right to Try Act

Bill Overview

Bill Number: SF 56
Title: A bill for an act relating to the Right to Try Act
Status: Committee report approving bill, renumbered as SF 233
Introduced: January 16, 2025
Classification: Bill
Subject Areas: Biological products, diseases, drugs, health insurance, informed consent, medical care, rights, terminal illnesses, third-party administrators

Purpose and Intent

The primary aim of SF 56 is to enhance access to investigational drugs, biological products, and devices for patients with terminal illnesses. The bill seeks to empower eligible patients to request and receive these treatments from manufacturers or eligible facilities, thereby expanding the rights of patients in dire health situations.

Key Provisions

  • Eligibility for Patients and Facilities: The bill stipulates that both manufacturers of investigational products and eligible facilities can provide individualized investigational treatments to patients who meet specific eligibility criteria.

  • Manufacturer's Rights: It amends existing provisions to ensure that manufacturers operating within eligible facilities can make investigational treatments available to patients without being mandated to provide these treatments.

  • Cost Considerations: The bill allows eligible facilities or manufacturers to provide individualized investigational treatments without requiring compensation from the patient. Additionally, patients will not be obligated to cover the costs associated with the manufacture of these treatments.

  • Compliance Requirements: The bill emphasizes that any manufacturer or facility providing these treatments must comply with all applicable federal and state requirements.

  • Conforming Changes: SF 56 includes necessary adjustments to existing code chapters to align with the new provisions introduced by the bill.

Impact

  • Patients: The bill primarily affects patients with terminal illnesses, granting them greater access to potentially life-saving investigational treatments that are not yet widely available.

  • Manufacturers and Facilities: Manufacturers of investigational drugs and eligible facilities will have clearer guidelines on their rights and responsibilities regarding the provision of treatments.

  • Healthcare System: The legislation may influence the dynamics of how investigational treatments are accessed and administered within the healthcare system, potentially leading to increased collaboration between manufacturers and healthcare providers.

Legislative Timeline

  • January 16, 2025: Bill introduced and referred to the Health and Human Services Committee.
  • January 21, 2025: Initial subcommittee formed to review the bill.
  • January 22, 2025: Subcommittee reassigned for further evaluation.
  • January 27, 2025: Subcommittee recommends passage of the bill.
  • February 10, 2025: Committee report approving the bill, which is then renumbered as SF 233.

This summary provides an overview of SF 56, detailing its purpose, key provisions, and potential impact on patients and the healthcare system. The bill represents a significant step toward improving access to investigational treatments for those facing terminal illnesses.

Compiled from official sources — confirm details with the bill’s official record.

Sign in to ask a question.